FDA Home Page | Search FDA Site | FDA A-Z Index | Contact FDA

Cellular, Tissue and Gene Therapies Advisory Committee (formerly Biological Response Modifiers Advisory Committee)

Agenda:
In open session, the committee will hear brief opening remarks and allow time for public participation and comments related to individual FDA research programs during the open public hearing. The committee will not hear presentations or discuss individual research programs in the open session ( see Closed Committee Deliberations below).

Background material and meeting information will become available no later than one business day before the meeting (Simply scroll down to the appropriate committee heading).

Closed Committee Deliberations:
On July 29, 2005 from approximately 1:30 p.m. to 2:30 p.m., the meeting will be closed to permit discussion where disclosure would constitute a clearly unwarranted invasion of personal privacy (5 U.S.C. 552b(c)(6)). The Committee will discuss a review of individual FDA research programs.

Procedure:
On July 29, 2005 from 12:30 p.m. to 1:30 p.m., the meeting is open to the public. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by July 21, 2005. Oral presentations from the public will be scheduled between approximately 12:30 p.m. to 1:30 p.m. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person by July 21, 2005 and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation. Persons attending FDA's advisory committee meetings are advised that the agency is not responsible for providing access to electrical outlets.

FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with physical disabilities or special needs. If you require special accommodations due to a disability, please contact Gail Dapolito at least 7 days in advance of the meeting.

Contact Person:
Gail Dapolito, Center for Biologics Evaluation and Research, Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852, 301-827-0314.

Advisory Committee Telephone Information Line:
Please call the Information Line for up-to-date information on this meeting, 1-800-741-8138 (301-443-0572 in the Washington, DC area), code 3014512389.